|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||28.57 - 29.96|
|52-week range||27.25 - 38.75|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||4.81|
|Earnings date||11 Nov 2021|
|Forward dividend & yield||1.12 (3.83%)|
|Ex-dividend date||19 Nov 2021|
|1y target est||40.50|
JERSEY CITY, N.J., November 11, 2021--Organon (NYSE: OGN) (the "company"), today announced its results for the third quarter and year to date ended September 30, 2021.
JERSEY CITY, N.J. & TURKU, Finland, November 11, 2021--Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral
Organon (NYSE: OGN) is pleased to announce NEXPLANON® (etonogestrel extended-release subdermal implant) public listing in Quebec under the Régie de l'assurance maladie du Québec (RAMQ) as of November 10. NEXPLANON® is a progestin-only hormonal implant used to prevent pregnancy for up to three years.1 Quebec is the fifth jurisdiction to list NEXPLANON® on its public formulary, including the Non-Insured Health Benefits program, Veterans Affairs Canada and the Saskatchewan Drug Plan.